Martignoni E, Pacchetti C, Aufdembrinke B, Godi L, Albani G, Mancini F, Nappi G
Department of Neurology, Parkinson's Disease Centre, IRCCS C. Mondino, University of Pavia, Italy.
Funct Neurol. 1995 May-Jun;10(3):143-6.
Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of "stable" patients (--those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score--remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained "stable" in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinsonian efficacy.
将41例稳定期帕金森病（PD）患者的泰舒达（TER）（2毫克/天）与安慰剂进行比较，以测试其作为左旋多巴（LD）节省辅助治疗的疗效。在辅助治疗第4周后，LD减少了约25%。使用LD减少后仍“稳定”（即哥伦比亚大学基础评分量表（CURS）评分增加不超过20%）的患者数量来比较两种辅助治疗。尽管LD减少，但大多数患者仍保持“稳定”，且未发现两种治疗方法之间有显著差异；仅TER组的CURS评分随时间下降。因此，泰舒达被证明是一种具有多巴胺能特性但抗帕金森病疗效最小的药物。
